Velcheti et al. [27] reported a novel method of in situ measurement of PD-L1 mRNA NanoString nCounter technology, suggesting its utility for the accurate measurement of PD-1/PDL-1 levels in predicting the response of lung adenocarcinoma patients to targeted immunotherapy. This evidence concerns the gene PDCD1 and lung adenocarcinoma.